Brief: Everest Medicines Sees Total Revenue Ranging Between RMB124 Mln And RMB126 Mln For Year
22/01/2024 01:00
Jan 22 (Reuters) - Everest Medicines Ltd 1952.HK :
* SEES TOTAL REVENUE RANGING BETWEEN RMB124 MILLION AND
RMB126
MILLION FOR YEAR
* EXPECTED RESULT DUE TO APPROVAL OF NEFECON IN MACAU IN OCT
2023,
AMONG OTHERS
Further company coverage: 1952.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Everest Medicines
See all newsBrief: Everest Medicines Says NMPA Approves Cardamyst (Etripamil) NDA For PSVT In Adults In China
Brief: Everest Medicines Enters Commercialization Collaboration With Hainan Herui Pharmaceutical
Brief: Everest Medicines Says CBC Group Purchases 712,000 Everest Medicines Shares For Hk$19.2 Million From 16 To 17 June
Australia's Dimerix soars on commercialisation deal with Everest Medicines
Brief: Dimerix Ltd Licenses Dmx200 To Everest For China And Asia Region